VistaGen Therapeutics, Inc.宣布,其用于治疗社交焦虑障碍急性发作的候选药物Fasedienol,在整个临床开发项目中已达到国际人用药品注册技术协调会(ICH)关于最低安全暴露的推荐标准。这一进展标志着该药物在安全性数据积累方面取得了重要里程碑,为其后续的临床推进和监管沟通奠定了关键基础。
VistaGen Therapeutics, Inc.宣布,其用于治疗社交焦虑障碍急性发作的候选药物Fasedienol,在整个临床开发项目中已达到国际人用药品注册技术协调会(ICH)关于最低安全暴露的推荐标准。这一进展标志着该药物在安全性数据积累方面取得了重要里程碑,为其后续的临床推进和监管沟通奠定了关键基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.